JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has granted tentative approval for the Company’s Abbreviated New Drug Application (ANDA) to market its generic version of GlaxoSmithKline’s antiviral product Valtrex® (Valacyclovir Hydrochloride) Tablets. Final approval of this ANDA is anticipated in December 2009. The brand product had annual sales of approximately $1.5 billion in the United States for the twelve months ended June 30, 2007, based on IMS sales data.
